glp-1/gip/glucagon receptor agonist Review Article: GLP‐1 Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD New strategies for the treatment

Unknown Long-Term Safety Profile: A short plasma half-life of under 30 minutes in rats and dogs, alongside low bioavailability after intramuscular administration, raises critical questions about what occurs with higher, repeated, or long-term exposures in humans

Dong HV, Robbins WA

Vitamin B6 can help regulate blood sugar levels

The study would not have been possible without the use of artificial intelligence to weed through dozens of proteins in a class called prohormones

Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8